800__O people__O develop__O CML__B-ORG each__O year__O in__O the__O UK__B-LOC and__O there__O are__O currently__O over__O 6,000__O patients__O with__O the__O disease.__O
The__O estimated__O cost__O to__O the__O NHS__B-MISC is__O &#163;290m__O pa__O and__O rising.__O
Due__O to__O his__O work__O on__O imatinib__O resistance__O and__O on__O nilotinib__O and__O dasatinib,__O Prof__B-PER Clark__I-PER became__O one__O of__O two__O experts__O co-opted__O by__O the__O National__B-ORG Institute__I-ORG of__I-ORG Clinical__I-ORG Excellence__I-ORG (NICE)__O to__O appraise__O these__O drugs,__O on__O behalf__O of__O the__O Royal__B-ORG College__I-ORG of__I-ORG Pathologists__I-ORG and__O the__O British__B-ORG Society__I-ORG for__O Haematology.__B-LOC
Based__O on__O the__O data__O of__O nilotinib__O superiority__O over__O imatinib__O in__O ENESTnd,__B-ORG on__O which__O Clark__B-PER was__O the__O UK__B-ORG Chief__I-ORG Investigator,__I-ORG and__O also__O the__O parallel__O study__O of__O dasatinib,__O NICE__B-ORG considered__O the__O use__O of__O second__O line__O nilotinib__O and__O dasatinib__O in__O a__O multitechnology__O appraisal__O from__O 2009-2011,__O resulting__O in__O approval__O for__O nilotinib__O but__O not__O dasatinib__O in__O January__O 2012__O [9].__O
NICE__B-ORG similarly__O involved__O Prof__B-PER Clark__I-PER in__O a__O second__O Technology__B-ORG Appraisal__I-ORG in__O 2012__O that__O recommended__O that__O nilotinib__O should__O also__O be__O approved__O for__O first__O line__O treatment__O of__O chronic__O phase__O CML__B-ORG [10].__I-ORG
Clark__O and__O the__O UoL's__B-MISC studies__O over__O the__O past__O few__O years__O have__O been__O key__O to__O this__O shift__O of__O the__O standard__O of__O care__O for__O newly__O diagnosed__O CML__B-ORG patients__O from__O imatinib__O to__O nilotinib.__O
A__O similar__O change__O from__O imatinib__O to__O nilotinib__O is__O also__O happening__O in__O most__O other__O Western__B-MISC countries,__O where__O their__O current__O clinical__O trials__O offer__O only__O nilotinib__O (with__O or__O without__O other__O treatments)__O to__O newly__O diagnosed__O CML__B-ORG patients.__O
Nilotinib__O (trade__O name__O Tasigna__B-PER )__O is__O licensed__O as__O first__O line__O therapy__O for__O newly__O diagnosed__O CML__B-ORG patients__O throughout__O the__O EU,__B-ORG Switzerland,__I-ORG Japan__I-ORG and__O the__O US,__B-ORG and__O as__O a__O second__O line__O treatment__O in__O over__O 100__O countries__O for__O patients__O resistant__O or__O intolerant__O to__O existing__O treatments__O [11].__B-ORG
The__O change__O to__O nilotinib__O as__O the__O treatment__O of__O choice__O [12]__B-ORG is__O underlined__O by__O the__O &#163;21.9m__B-MISC industry__O funded__O SPIRIT__B-ORG 3__O trial__O that__O will__O soon__O be__O underway__O in__O the__O UK__B-LOC (as__O of__O November__O 2013,__O applications__O for__O ethical__O and__O MHRA__B-ORG approval__O are__O currently__O under__O consideration__O but__O see__O next__O paragraph).__O
This__O randomised__O phase__O III__B-PER trial__O intends__O to__O recruit__O 1,000__O newly__O diagnosed__O chronic__O phase__O CML__B-ORG patients.__O
It__O will__O examine__O whether__O nilotinib__O remains__O a__O superior__O treatment__O to__O imatinib__O if__O patients__O who__O have__O inadequate__O early__O molecular__O responses__O are__O offered__O an__O early__O switch__O of__O treatment.__O
The__O trial__O will__O also__O examine__O whether__O treatment__O de-__O escalation__O and__O then__O cessation__O can__O be__O achieved__O in__O patients__O with__O excellent__O and__O sustained__O treatment__O responses__O for__O some__O years,__O in__O case__O these__O patients__O are__O functionally__O cured__O [13].__O
This__O de-escalation__O and__O stopping__O strategy__O is__O being__O piloted__O in__O a__O phase__O II__B-MISC trial__O called__O DESTINY,__B-ORG led__O from__O Liverpool__B-ORG and__O for__O which__O Clark__O is__O the__O Chief__O Investigator__O (supported__O by__O Leukaemia__B-ORG &amp;__I-ORG Lymphoma__I-ORG Research)__I-ORG which__O is__O opening__O in__O November__O 2013.__O
However,__O during__O 2013__O several__O reports__O have__O emerged__O on__O a__O small__O apparent__O excess__O of__O cardiovascular__O events__O on__O nilotinib__O than__O imatinib.__O
It__O is__O not__O possible__O to__O be__O certain__O on__O this__O as__O ENESTnd__O and__O smaller__O studies__O were__O not__O designed__O to__O test__O this.__O
In__O addition,__O on__O October__O 8th__O 2013,__O the__O US__B-ORG Food__I-ORG &amp;__I-ORG Drugs__I-ORG Administration__I-ORG unexpectedly__O announced__O an__O investigation__O into__O cardiovascular__O events__O in__O patients__O receiving__O ponatinib,__O a__O 3rd__O generation__O TKI__B-MISC that__O is__O part__O of__O the__O `early__O switch'__O strategy__O in__O the__O UK__B-LOC SPIRIT3__O trial.__O
Interest__O in__O nilotinib__O (and__O ponatinib)__O has__O therefore__O evolved__O to__O determining__O whether__O cardiovascular__O events__O are__O a__O genuine__O and__O clinically__O relevant__O unwanted__O effect,__O and__O also__O on__O the__O underlying__O mechanism.__O
Finally,__O the__O UoL__B-ORG group's__O scientific__O observations__O have__O also__O had__O clinical__O impact,__O partly__O in__O relation__O to__O the__O switch__O from__O imatinib__O to__O nilotinib.__O
The__O UoL's__B-MISC demonstration__O of__O HLA-associated__B-MISC expression__O of__O BCR-ABL__B-ORG fusion__O peptides__O [6]__O led__O directly__O to__O several__O studies__O of__O peptide__O vaccination__O in__O CML__O and__O other__O leukaemias__O [14].__O
There__O is__O also__O much__O interest__O in__O biomarkers__O in__O CML,__O to__O predict__O a__O poor__O clinical__O outcome__O (transformation__O to__O acute__O leukaemia),__O and__O the__O UoL's__B-ORG identification__O of__O CIP2A__B-ORG [7]__O has__O evolved__O into__O a__O more__O thorough__O study__O of__O this__O protein__O in__O many__O other__O cancers__O (exemplified__O by__O 30__O further__O reports__O on__O CIP2A__B-ORG in__O the__O 2__O years__O since__O publication).__O
The__O most__O recent__O data__O in__O Liverpool__B-ORG indicate__O that__O while__O CML__B-ORG patients__O with__O high__O CIP2A__B-ORG expression__O have__O a__O high__O probability__O of__O disease__O progression__O to__O blast__O crisis__O if__O treated__O with__O imatinib,__O this__O is__O not__O true__O if__O receiving__O nilotinib,__O and__O that__O this__O may__O be__O due__O to__O differential__O effects__O of__O the__O two__O drugs__O on__O various__O ancillary__O proteins__O involved__O in__O CIP2A__B-ORG regulation__O (data__O presented__O at__O the__O European__B-ORG School__I-ORG of__I-ORG Haematology__I-ORG 2013__O and__O manuscript__O submitted__O to__O a__O high__O impact__O journal__O in__O November__O 2013__O [15]).__O
These__O laboratory__O observations__O support__O the__O case__O that__O high__O CIP2A__B-ORG expressing__O patients__O should__O preferentially__O receive__O nilotinib__O from__O original__O diagnosis.__O
